-
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
Thursday, April 20, 2023 - 9:02am | 600The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started recruiting participants for the first-ever clinical trial assessing the effects of psilocybin in adults diagnosed with Fragile X Syndrome (FXS), the leading genetic...
-
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Tuesday, February 14, 2023 - 2:37pm | 366Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder. KGK and its client Nova Mentis (OTC: NMLSF) are set to conduct this pioneering...
-
Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn
Thursday, September 29, 2022 - 2:36pm | 242Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry, manufacturing and controls (CMC) published guidelines. NOVA’s new compounds would be used in...
-
Wellbeing Digital Reports 4Q Finances, 'Three Key Pillars' Stay Strong
Friday, September 16, 2022 - 4:05pm | 349Wellbeing Digital Sciences Inc. (OTC: KONEF) filed its financial results for the quarter ended July 31, 2022 and provided some insight on their most recent businesses. Numbers for the selected period showed: Total revenue of $872.731 (CA$1,160,547), representing a 2.5% increase compared to...